{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:30:45Z","timestamp":1791664245634,"version":"4.3.4"},"reference-count":157,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Resistance of Cutibacterium acnes to topical antibiotics historically used to treat acne (topical erythromycin and clindamycin and, more recently, topical azithromycin and clarithromycin) has been steadily increasing and new topical antibiotics are needed. Minocycline is a semisynthetic tetracycline-derived antibiotic currently used systemically to treat a wide range of infections caused by Gram-negative and Gram-positive bacteria. In addition to its antibiotic activity, minocycline possesses anti-inflammatory properties, such as the downregulation of proinflammatory cytokine production, suppression of neutrophil chemotaxis, activation of superoxide dismutase, and inhibition of phagocytosis, among others. These characteristics make minocycline a valuable agent for treatment of dermatological diseases such as acne vulgaris and papulopustular rosacea. However, more frequent or serious adverse effects have been observed upon the systemic administration of minocycline than with other tetracyclines. Examples of serious adverse effects include hypersensitivity syndrome reaction, drug-induced lupus, idiopathic intracranial hypertension, and other autoimmune syndromes that may cause death. Here, we review adverse effects and drug\u2013drug interactions observed with oral administration of minocycline and contrast this with topical minocycline formulations recently approved or under development for effectively treating dermatological disorders with fewer adverse effects and less drug interaction.<\/jats:p>","DOI":"10.3390\/antibiotics10070757","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T13:02:10Z","timestamp":1624366930000},"page":"757","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["A Review of Systemic Minocycline Side Effects and Topical Minocycline as a Safer Alternative for Treating Acne and Rosacea"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4822-3249","authenticated-orcid":false,"given":"Ana M.","family":"Martins","sequence":"first","affiliation":[{"name":"Research Institute for Medicine (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5523-5622","authenticated-orcid":false,"given":"Joana M.","family":"Marto","sequence":"additional","affiliation":[{"name":"Research Institute for Medicine (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8328-5587","authenticated-orcid":false,"given":"Jodi L.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmy M.","family":"Graber","sequence":"additional","affiliation":[{"name":"The Dermatology Institute, Boston, MA 02116, USA"},{"name":"Northeastern University, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/clinids\/7.5.702","article-title":"Some historical notes on chlortetracycline","volume":"7","author":"Jukes","year":"1985","journal-title":"Rev. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00007691-198206000-00002","article-title":"Minocycline","volume":"4","author":"Jonas","year":"1982","journal-title":"Ther. Drug Monit."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Graber, E.M. (2021). Treating acne with the tetracycline class of antibiotics: A review. Dermatol. Rev.","DOI":"10.1002\/der2.49"},{"key":"ref_4","first-page":"e01297","article-title":"Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris","volume":"63","author":"Zhanel","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","article-title":"Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance","volume":"65","author":"Chopra","year":"2001","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bph.12139","article-title":"Minocycline: Far beyond an antibiotic","volume":"169","author":"Zarzuelo","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_7","first-page":"371","article-title":"Antibacterial activity in mice of minocycline, a new tetracycline","volume":"6","author":"Redin","year":"1966","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","unstructured":"(2021, June 13). Solodyn (Minocycline Hydrochloride) Extended Release Tablets, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/050808s000TOC.cfm."},{"key":"ref_9","unstructured":"(2021, February 18). Minocycline (Topical). Available online: https:\/\/www.drugs.com\/monograph\/minocycline-topical.html."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2005.10.004","article-title":"Tetracyclines: Nonantibiotic properties and their clinical implications","volume":"54","author":"Sapadin","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1540-9740.2003.03014.x","article-title":"Subantimicrobial dose doxycycline for acne and rosacea","volume":"2","author":"Bikowski","year":"2003","journal-title":"Skinmed"},{"key":"ref_12","first-page":"282","article-title":"Incidence and prevalence of rosacea: A systematic review and meta-analysis","volume":"179","author":"Gether","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Buddenkotte, J., and Steinhoff, M. (2018). Recent advances in understanding and managing rosacea. F1000Research, 7.","DOI":"10.12688\/f1000research.16537.1"},{"key":"ref_14","unstructured":"Farshchian, M., and Daveluy, S. (2020). Rosacea, StatPearls."},{"key":"ref_15","first-page":"348","article-title":"Burden of Disease: The Psychosocial Impact of Rosacea on a Patient\u2019s Quality of Life","volume":"6","author":"Huynh","year":"2013","journal-title":"Am. Health Drug Benefits"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jid.2020.02.025","article-title":"Rosacea is Characterized by a Profoundly Diminished Skin Barrier","volume":"140","author":"Medgyesi","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/exd.12251","article-title":"Acute irritant threshold correlates with barrier function, skin hydration and contact hypersensitivity in atopic dermatitis and rosacea","volume":"22","author":"Darlenski","year":"2013","journal-title":"Exp. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2133.2011.10590.x","article-title":"Interventions for \u2018rosacea\u2019","volume":"165","author":"Powell","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bjd.12149","article-title":"Epidemiology of acne vulgaris","volume":"168","author":"Bhate","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijwd.2017.10.006","article-title":"A review of diagnosis and treatment of acne in adult female patients","volume":"4","author":"Tan","year":"2018","journal-title":"Int. J. Womens Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","first-page":"503","article-title":"Acne and acne scarring - the case for active and early intervention","volume":"35","author":"Goodman","year":"2006","journal-title":"Aust. Fam. Physician"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/jdv.16686","article-title":"Antibiotic resistance in acne: Changes, consequences and concerns","volume":"35","author":"Karadag","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_24","first-page":"60","article-title":"An Update on the Use of Minocycline for the Treatment of Acne","volume":"2020","author":"Zeichner","year":"2020","journal-title":"Pract. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/11530200-000000000-00000","article-title":"The role of tetracyclines in rosacea","volume":"11","author":"Alikhan","year":"2010","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/jamadermatol.2018.4944","article-title":"Trends in Oral Antibiotic Prescription in Dermatology, 2008 to 2016","volume":"155","author":"Barbieri","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_27","first-page":"437","article-title":"Clinical Implications of Minocycline Use in Acne Vulgaris: Focus on Antimicrobial and Anti-inflammatory Properties","volume":"21","year":"2008","journal-title":"Cosmet. Dermatol."},{"key":"ref_28","first-page":"118","article-title":"A status report on the use of subantimicrobial-dose doxycycline: A review of the biologic and antimicrobial effects of the tetracyclines","volume":"74","year":"2004","journal-title":"Cutis"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10787-011-0077-5","article-title":"Anti-inflammatory properties of doxycycline and minocycline in experimental models: An in vivo and in vitro comparative study","volume":"19","author":"Leite","year":"2011","journal-title":"Inflammopharmacology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000017852","article-title":"Comedonal diffusion of minocycline in acne","volume":"196","author":"Chosidow","year":"1998","journal-title":"Dermatology"},{"key":"ref_31","unstructured":"(2021, February 26). Minocycline. Available online: https:\/\/go.drugbank.com\/drugs\/DB01017."},{"key":"ref_32","unstructured":"(2021, February 18). Minocycline Hydrochloride, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=050315."},{"key":"ref_33","unstructured":"Dinnendahl, V., and Minocyclin, F.U. (2010). Basisinformation \u00fcber arzneiliche Wirkstoffe. Arzneistoff-Profile, Govi Pharmazeutischer Verlag. (In German)."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"i7","DOI":"10.1093\/jac\/dkt022","article-title":"Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: Results of the CANWARD 2007-11 study","volume":"68","author":"Zhanel","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1592\/phco.26.4.515","article-title":"Minocycline for short-term neuroprotection","volume":"26","author":"Elewa","year":"2006","journal-title":"Pharmacotherapy"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00003495-197509040-00005","article-title":"Minocycline: A review of its antibacterial and pharmacokinetic properties and therapeutic use","volume":"9","author":"Brogden","year":"1975","journal-title":"Drugs"},{"key":"ref_37","first-page":"21","article-title":"Safety and efficacy of a new extended-release formulation of minocycline","volume":"78","author":"Fleischer","year":"2006","journal-title":"Cutis"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000051728","article-title":"Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris","volume":"203","author":"Dreno","year":"2001","journal-title":"Dermatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1099\/mic.0.040618-0","article-title":"Long-term impacts of antibiotic exposure on the human intestinal microbiota","volume":"156","author":"Jernberg","year":"2010","journal-title":"Microbiology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/B978-0-12-818882-8.00016-4","article-title":"Toxicity of Antibiotics","volume":"Volume 1","author":"Rehman","year":"2020","journal-title":"Antibiotics and Antimicrobial Resistance Genes in the Environment"},{"key":"ref_41","first-page":"1543","article-title":"Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances","volume":"6","author":"Francino","year":"2015","journal-title":"Front. Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/jcp.28.5.403","article-title":"Effects of minocycline and tetracycline on the vaginal yeast flora","volume":"28","author":"Oriel","year":"1975","journal-title":"J. Clin. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Garner, S.E., Eady, A., Bennett, C., Newton, J.N., Thomas, K., and Popescu, C.M. (2012). Minocycline for acne vulgaris: Efficacy and safety. Cochrane Database Syst. Rev., CD002086.","DOI":"10.1002\/14651858.CD002086.pub2"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2133.1996.tb06972.x","article-title":"Safety of long-term high-dose minocycline in the treatment of acne","volume":"134","author":"Goulden","year":"1996","journal-title":"Br. J. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1365-2133.2012.10845.x","article-title":"Comparative analysis of adverse drug reactions to tetracyclines: Results of a French national survey and review of the literature","volume":"166","author":"Castot","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/archderm.1997.03890460044005","article-title":"Comparative safety of tetracycline, minocycline, and doxycycline","volume":"133","author":"Shapiro","year":"1997","journal-title":"Arch. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Hamilton, L.A., and Guarascio, A.J. (2019). Tetracycline Allergy. Pharmacy, 7.","DOI":"10.3390\/pharmacy7030104"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0190-9622(97)80414-8","article-title":"Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: A severe adverse reaction to minocycline","volume":"36","author":"MacNeil","year":"1997","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"606","DOI":"10.4103\/0253-7613.190766","article-title":"VigiAccess: Promoting public access to VigiBase","volume":"48","author":"Shankar","year":"2016","journal-title":"Indian J. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1128\/AAC.12.5.642","article-title":"Side effects of minocycline: Different dosage regimens","volume":"12","author":"Gump","year":"1977","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000112926","article-title":"Minocycline-induced DRESS: Evidence for accumulation of the culprit drug","volume":"216","author":"Maubec","year":"2008","journal-title":"Dermatology"},{"key":"ref_52","first-page":"19","article-title":"Oral Doxycycline in the Management of Acne Vulgaris: Current Perspectives on Clinical Use and Recent Findings with a New Double-scored Small Tablet Formulation","volume":"8","year":"2015","journal-title":"J. Clin. Aesthetic Dermatol."},{"key":"ref_53","first-page":"409","article-title":"VigiBase, the WHO Global ICSR Database System: Basic Facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_54","first-page":"1407","article-title":"Doxycycline and minocycline for the management of acne: A review of efficacy and safety with emphasis on clinical implications","volume":"9","author":"Kircik","year":"2010","journal-title":"J. Drugs Dermatol."},{"key":"ref_55","unstructured":"(2021, February 18). Pseudotumor Cerebri Information Page: What Research is Being Done?, Available online: https:\/\/www.ninds.nih.gov\/Disorders\/All-Disorders\/Pseudotumor-Cerebri-Information-Page."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0753-3322(92)90026-4","article-title":"Minocycline and benign intracranial hypertension","volume":"46","author":"Donnet","year":"1992","journal-title":"Biomed. Pharmacother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/08820538.2016.1228415","article-title":"Medication-Related Pseudotumor Cerebri Syndrome","volume":"32","author":"Thon","year":"2017","journal-title":"Semin. Ophthalmol."},{"key":"ref_58","first-page":"169","article-title":"Pseudotumor cerebri due to taking minocycline","volume":"38","author":"Kaabour","year":"2017","journal-title":"Rev. Med. Brux."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/archneurol.2012.144","article-title":"Minocycline-induced fulminant intracranial hypertension","volume":"69","author":"Fraser","year":"2012","journal-title":"Arch. Neurol."},{"key":"ref_60","first-page":"165","article-title":"Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne","volume":"55","author":"Lee","year":"1995","journal-title":"Cutis"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.concog.2010.10.018","article-title":"Depersonalization: A selective impairment of self-awareness","volume":"20","author":"Sierra","year":"2011","journal-title":"Conscious. Cogn."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.SMJ.0000083857.98870.98","article-title":"Medication-associated depersonalization symptoms: Report of transient depersonalization symptoms induced by minocycline","volume":"97","author":"Cohen","year":"2004","journal-title":"South Med. J."},{"key":"ref_63","first-page":"2050313X18823827","article-title":"Minocycline-induced transient depersonalization: A case report","volume":"7","author":"Shamout","year":"2019","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1073\/pnas.83.13.4604","article-title":"Phototoxicity of the tetracyclines: Photosensitized emission of singlet delta dioxygen","volume":"83","author":"Hasan","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.clindermatol.2016.05.006","article-title":"Drug-induced photosensitivity: Photoallergic and phototoxic reactions","volume":"34","author":"Monteiro","year":"2016","journal-title":"Clin. Dermatol."},{"key":"ref_66","first-page":"987","article-title":"Once-Daily Oral Sarecycline 1.5 mg\/kg\/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials","volume":"17","author":"Moore","year":"2018","journal-title":"J. Drugs Dermatol."},{"key":"ref_67","first-page":"46","article-title":"Minocycline-induced hyperpigmentation involving the oral mucosa after short-term minocycline use","volume":"92","author":"Filitis","year":"2013","journal-title":"Cutis"},{"key":"ref_68","first-page":"1","article-title":"Minocycline-induced hyperpigmentation","volume":"4","author":"Fiscus","year":"2014","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/OPX.0000000000001024","article-title":"Minocycline-Induced Scleral and Dermal Hyperpigmentation","volume":"94","author":"Haskes","year":"2017","journal-title":"Optom. Vis. Sci."},{"key":"ref_70","first-page":"123","article-title":"Minocycline-induced skin pigmentation: An update","volume":"17","author":"Geria","year":"2009","journal-title":"Acta Dermatovenerol. Croat."},{"key":"ref_71","first-page":"644","article-title":"Drug-induced hperpigemntation: A systematic review","volume":"11","author":"Krause","year":"2013","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_72","first-page":"360","article-title":"Bilateral Tarsal Conjunctival Pigmentation After Eight Months of Minocycline Therapy","volume":"73","author":"Kudrna","year":"2020","journal-title":"S. D. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e183088","DOI":"10.1001\/jamaophthalmol.2018.3088","article-title":"Long-term Minocycline Therapy With Scleral Pigmentation Simulating Melanocytosis","volume":"136","author":"Maloney","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1111\/1346-8138.14995","article-title":"Case of minocycline-induced hyperpigmentation mimicking angiosarcoma","volume":"46","author":"Yokoi","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/archderm.1995.01690170124028","article-title":"Black tongue associated with minocycline therapy","volume":"131","author":"Katz","year":"1995","journal-title":"Arch. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archderm.136.3.427","article-title":"Minocycline-induced hyperpigmentation of the tongue","volume":"136","author":"Tanzi","year":"2000","journal-title":"Arch. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-4632.2004.02108.x","article-title":"Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity","volume":"43","author":"Sanchez","year":"2004","journal-title":"Int. J. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1365-2133.2003.05497.x","article-title":"Minocycline: Stain devil?","volume":"149","author":"Good","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.jaad.2007.05.032","article-title":"Perinuclear antineutrophilic cytoplasmic antibody-positive polyarteritis nodosa secondary to minocycline treatment for acne vulgaris","volume":"58","author":"Gait","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0049-0172(99)80004-3","article-title":"Minocycline-induced autoimmune syndromes: An overview","volume":"28","author":"Elkayam","year":"1999","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1365-2133.2007.07828.x","article-title":"Is minocycline therapy in acne associated with antineutrophil cytoplasmic antibody positivity? A cross-sectional study","volume":"156","author":"Baxter","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_82","first-page":"240","article-title":"Treating Acne With Topical Antibiotics: Current Obstacles and the Introduction of Topical Minocycline as a New Treatment Option","volume":"18","author":"Bonati","year":"2019","journal-title":"J. Drugs Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/archdermatol.2008.521","article-title":"Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae","volume":"145","author":"Brown","year":"2009","journal-title":"Arch. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/PEC.0000000000001188","article-title":"DRESS Syndrome: Drug Reaction With Eosinophilia and Systemic Symptoms","volume":"33","author":"Corneli","year":"2017","journal-title":"Pediatric Emerg. Care"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaad.2009.05.046","article-title":"Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis","volume":"62","author":"Shaughnessy","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2230.2010.03967.x","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): A clinical update and review of current thinking","volume":"36","author":"Walsh","year":"2011","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e003665","DOI":"10.1161\/CIRCHEARTFAILURE.116.003665","article-title":"Treatment of Acute Necrotizing Eosinophilic Myocarditis With Immunosuppression and Mechanical Circulatory Support","volume":"9","author":"Howell","year":"2016","journal-title":"Circ. Heart Fail"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/1346-8138.12378","article-title":"Drug-induced hypersensitivity syndrome due to minocycline complicated by severe myocarditis","volume":"41","author":"Kanno","year":"2014","journal-title":"J. Dermatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5811\/cpcem.2018.11.40569","article-title":"Use of Emergency Department Extracorporeal Membrane Oxygenation for Treatment of Acute Necrotizing Myocarditis","volume":"3","author":"Loner","year":"2019","journal-title":"Clin. Pract. Cases Emerg. Med."},{"key":"ref_90","first-page":"107","article-title":"Fever, eosinophilia, and death: A case of minocycline hypersensitivity","volume":"93","author":"Wu","year":"2014","journal-title":"Cutis"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3389\/fimmu.2017.00484","article-title":"Eosinophils in Autoimmune Diseases","volume":"8","author":"Diny","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"978","DOI":"10.12659\/AJCR.909569","article-title":"Myocarditis Associated with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Case Report and Review of the Literature","volume":"19","author":"Morikawa","year":"2018","journal-title":"Am. J. Case Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archderm.1995.01690160120024","article-title":"Minocycline as possible cause of severe and protracted hypersensitivity drug reaction","volume":"131","author":"Lobut","year":"1995","journal-title":"Arch. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2015.12.010","article-title":"A severe case of minocycline-induced DRESS resulting in liver transplantation and autoimmune sequelae","volume":"116","author":"Lan","year":"2016","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_95","first-page":"301","article-title":"Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms","volume":"137","author":"Descamps","year":"2001","journal-title":"Arch. Dermatol."},{"key":"ref_96","unstructured":"Solhjoo, M., Bansal, P., Goyal, A., and Chauhan, K. (2020). Drug-Induced Lupus Erythematosus, StatPearls."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/archderm.1996.03890320082013","article-title":"Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature","volume":"132","author":"Knowles","year":"1996","journal-title":"Arch. Dermatol."},{"key":"ref_98","first-page":"239","article-title":"Severe complication of a commonly prescribed drug: Minocycline-induced lupus","volume":"15","author":"Shepherd","year":"2002","journal-title":"J. Am. Board Fam. Pract."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.1365-2133.2000.03357.x","article-title":"Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome","volume":"142","author":"Dunphy","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000018387","article-title":"Minocycline-induced lupus","volume":"200","author":"Schlienger","year":"2000","journal-title":"Dermatology"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Clark, A.K., Shi, V.Y., and Sivamani, R.K. (2017). Unique urticarial presentation of minocycline-induced lupus erythematosus. Dermatol. Online J., 23.","DOI":"10.5070\/D3238036005"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01720610-200803000-00009","article-title":"A serum sickness-like reaction to a commonly used acne drug","volume":"21","author":"Bettge","year":"2008","journal-title":"JAAPA"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2500\/108854196778645038","article-title":"Minocycline-induced serum sickness","volume":"17","author":"Levenson","year":"1996","journal-title":"Allergy Asthma Proc."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1398-9995.1990.tb00502.x","article-title":"Serum sickness-like syndrome associated with minocycline therapy","volume":"45","author":"Puyana","year":"1990","journal-title":"Allergy"},{"key":"ref_105","first-page":"100","article-title":"Is serum sickness an uncommon adverse effect of minocycline treatment?","volume":"137","author":"Malakar","year":"2001","journal-title":"Arch. Dermatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10067-013-2245-z","article-title":"ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: Case-based review","volume":"32","author":"Lenert","year":"2013","journal-title":"Clin. Rheumatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/RHU.0b013e3180690693","article-title":"Minocycline-induced cutaneous polyarteritis nodosa","volume":"13","author":"Tehrani","year":"2007","journal-title":"J. Clin. Rheumatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: Summary report--Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3346\/jkms.2010.25.8.1231","article-title":"A case of anaphylaxis to oral minocycline","volume":"25","author":"Jang","year":"2010","journal-title":"J Korean Med. Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2340\/0001555576164164","article-title":"Anaphylactoid symptoms due to oral minocycline","volume":"76","author":"Okano","year":"1996","journal-title":"Acta Derm. Venereol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e9688","DOI":"10.1097\/MD.0000000000009688","article-title":"Drug-induced eosinophilic pneumonia: A review of 196 case reports","volume":"97","author":"Bartal","year":"2018","journal-title":"Medicine"},{"key":"ref_112","first-page":"110","article-title":"Minocycline-induced acute eosinophilic pneumonia: A case report and review of the literature","volume":"15","author":"Hung","year":"2015","journal-title":"Respir. Med. Case Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1164\/rccm.2112056","article-title":"Idiopathic acute eosinophilic pneumonia: A study of 22 patients","volume":"166","author":"Philit","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1901380","DOI":"10.1183\/13993003.01380-2019","article-title":"A major genetic determinant of autoimmune diseases is associated with the presence of autoantibodies in hypersensitivity pneumonitis","volume":"56","author":"Mejia","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jaci.2018.09.040","article-title":"Hypersensitivity pneumonitis: A fibrosing alveolitis produced by inhalation of diverse antigens","volume":"143","author":"Greenberger","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2500\/aap.2019.40.4263","article-title":"Hypersensitivity pneumonitis","volume":"40","author":"Watts","year":"2019","journal-title":"Allergy Asthma Proc."},{"key":"ref_117","unstructured":"(2021, June 13). Solodyn. Available online: https:\/\/www.rxlist.com\/solodyn-drug.htm#description."},{"key":"ref_118","unstructured":"(2020, July 24). Drugs and Lactation Database (LactMed). Minocycline, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501031\/."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.mcna.2006.06.008","article-title":"Antibiotic drug interactions","volume":"90","author":"Pai","year":"2006","journal-title":"Med. Clin. N. Am."},{"key":"ref_120","unstructured":"(2021, February 27). Minocycline Drug Interactions. Available online: https:\/\/www.drugs.com\/drug-interactions\/minocycline.html."},{"key":"ref_121","unstructured":"(2021, March 30). Questions and Answers for Consumers on Doxycycline, Available online: https:\/\/www.fda.gov\/drugs\/bioterrorism-and-drug-preparedness\/questions-and-answers-consumers-doxycycline."},{"key":"ref_122","first-page":"853","article-title":"Drug interactions between oral contraceptives and antibiotics","volume":"98","author":"Dickinson","year":"2001","journal-title":"Obstet. Gynecol."},{"key":"ref_123","first-page":"416","article-title":"The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone","volume":"77","author":"Neely","year":"1991","journal-title":"Obstet. Gynecol."},{"key":"ref_124","unstructured":"Foamix Pharmaceuticals Ltd (2019). Foamix Receives FDA Approval of AMZEEQ\u2122 Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers, Foamix Pharmaceuticals Ltd."},{"key":"ref_125","unstructured":"(2020). Minocycline foam (Amzeeq) for acne. Med. Lett. Drugs Ther., 62, 68\u201370."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1060028020939926","article-title":"Minocycline Topical Foam: A New Drug for the Treatment of Acne","volume":"55","author":"Onge","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_127","unstructured":"(2020). Minocycline foam (Zilxi) for rosacea. Med. Lett. Drugs Ther., 62, 179\u2013180."},{"key":"ref_128","first-page":"630","article-title":"Vehicle Effects on the Rosacea Skin Barrier","volume":"20","author":"Draelos","year":"2021","journal-title":"J. Drugs Dermatol."},{"key":"ref_129","unstructured":"Hovione (2019). Hovione Announces Successful End-of-phase 2 Meeting With the FDA and Outlines Phase 3 Program for Minocycline Topical Gel, Hovione."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/bjd.18857","article-title":"A multicentre, randomized, double-masked, parallel group, vehicle-controlled phase IIb study to evaluate the safety and efficacy of 1% and 3% topical minocycline gel in patients with papulopustular rosacea","volume":"183","author":"Webster","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_131","unstructured":"BioPharmX Corporation (2019). BioPharmX Announces Positive Topline Results from Phase 2b Trial of BPX-04 for Papulopustular Rosacea, BioPharmX Corporation."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/10717544.2019.1709921","article-title":"Minocycline-loaded PLGA electrospun membrane prevents alveolar bone loss in experimental peridontitis","volume":"27","author":"Ma","year":"2020","journal-title":"Drug Deliv."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Schmid, J.L., Kirchberg, M., Sarembe, S., Kiesow, A., Sculean, A., Mader, K., Buchholz, M., and Eick, S. (2020). In Vitro Evaluation of Antimicrobial Activity of Minocycline Formulations for Topical Application in Periodontal Therapy. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12040352"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Yang, Z., Liang, X., Jiang, X., Guo, J., Tao, Y., Wang, S., Cao, Y., and Gui, S. (2018). Development and Evaluation of Minocycline Hydrochloride-Loaded In Situ Cubic Liquid Crystal for Intra-Periodontal Pocket Administration. Molecules, 23.","DOI":"10.3390\/molecules23092275"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/02652048.2018.1487472","article-title":"Design of minocycline-containing starch nanocapsules for topical delivery","volume":"35","author":"Marto","year":"2018","journal-title":"J. Microencapsul."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Marto, J., Duarte, A., Simoes, S., Goncalves, L.M., Gouveia, L.F., Almeida, A.J., and Ribeiro, H.M. (2019). Starch-Based Pickering Emulsions as Platforms for Topical Antibiotic Delivery: In Vitro and In Vivo Studies. Polymers, 11.","DOI":"10.3390\/polym11010108"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2018.08.020","article-title":"A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies","volume":"80","author":"Gold","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jaad.2020.01.043","article-title":"Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials","volume":"82","author":"Gold","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_139","first-page":"25","article-title":"BPX-01 Minocycline Topical Gel Shows Promise for the Treatment of Moderate-to-severe Inflammatory Acne Vulgaris","volume":"11","author":"Alexis","year":"2018","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_140","unstructured":"(2021, February 19). BPX-04. Available online: https:\/\/www.biopharmx.com\/pipeline\/bpx-04-rosacea\/."},{"key":"ref_141","unstructured":"BioPharmX Corporation (2019). BioPharmX Receives Concurrence from FDA on Phase 3 Acne Study Plans, BioPharmX Corporation."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","article-title":"Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea","volume":"56","author":"Webster","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_143","first-page":"187","article-title":"Rosacea: Diagnosis and Treatment","volume":"92","author":"Oge","year":"2015","journal-title":"Am. Fam. Physician"},{"key":"ref_144","first-page":"1486","article-title":"Oral antibiotics versus topical decolonization to prevent surgical site infection after Mohs micrographic surgery\u2014A randomized, controlled trial","volume":"39","author":"Cherian","year":"2013","journal-title":"Dermatol. Surg."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijpharm.2010.03.024","article-title":"Gel characterisation and in vivo evaluation of minocycline-loaded wound dressing with enhanced wound healing using polyvinyl alcohol and chitosan","volume":"392","author":"Sung","year":"2010","journal-title":"Int. J. Pharm."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1208\/s12249-014-0118-7","article-title":"Comparative study to investigate the effect of meloxicam or minocycline HCl in situ gel system on local treatment of periodontal pockets","volume":"15","author":"Kassem","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1086\/598510","article-title":"Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300","volume":"48","author":"Schwartz","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_148","first-page":"1022","article-title":"Pharmacokinetic Comparison of Once-Daily Topical Minocycline Foam 4% vs Oral Minocycline for Moderate-to-Severe Acne","volume":"16","author":"Jones","year":"2017","journal-title":"J. Drugs Dermatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jaad.2019.05.078","article-title":"Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: A phase 3 study","volume":"82","author":"Raoof","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1590\/s1806-37562018000000028","article-title":"Eosinophilic pneumonia: Remember topical drugs as a potential etiology","volume":"44","author":"Dias","year":"2018","journal-title":"J. Bras. Pneumol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/09546634.2016.1214234","article-title":"The extinction of topical erythromycin therapy for acne vulgaris and concern for the future of topical clindamycin","volume":"28","author":"Austin","year":"2017","journal-title":"J. Dermatolog. Treat."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40257-020-00523-1","article-title":"Topical Minocycline Foam 4%: A Review in Acne Vulgaris","volume":"21","author":"Paik","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Sutcliffe, J., McLaughlin, R., Del Rosso, J., Weiss, J., Baldwin, H., Webster, G., Leyden, J., Zhao, X., Read, A., and Drlica, K. (2019, January 8\u201311). Assessing Bacterial Susceptibility to FMX101 4% Topical Minocycline Foam. Proceedings of the Society for Investigative Dermatology, Chicago, IL, USA.","DOI":"10.1016\/j.jid.2019.06.084"},{"key":"ref_154","unstructured":"(2021, April 04). Amzeeq. Available online: https:\/\/www.drugs.com\/pro\/amzeeq.html."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"(2013). Time to say goodbye to minocycline?. Drug Ther. Bull., 51, 49.","DOI":"10.1136\/dtb.2013.5.0176"},{"key":"ref_156","unstructured":"(2021, February 19). Minocycline. Available online: https:\/\/www.nice.org.uk\/advice\/ktt11\/resources\/minocycline-pdf-58757947696069."},{"key":"ref_157","first-page":"100009","article-title":"Topical minocycline formulations: Evaluation and comparison of dermal uptake efficacy","volume":"1","author":"Lac","year":"2019","journal-title":"Int. J. Pharm. X"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/7\/757\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:21:07Z","timestamp":1760163667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/7\/757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":157,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["antibiotics10070757"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10070757","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]}}}